Provided by Tiger Trade Technology Pte. Ltd.

Xenon Pharmaceuticals

60.42
-0.1400-0.23%
Post-market: 60.420.00000.00%16:10 EDT
Volume:418.01K
Turnover:25.32M
Market Cap:5.84B
PE:-12.84
High:61.67
Open:61.01
Low:60.26
Close:60.56
52wk High:72.66
52wk Low:35.60
Shares:96.64M
Float Shares:95.45M
Volume Ratio:0.59
T/O Rate:0.44%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.7061
EPS(LYR):-4.3646
ROE:-43.62%
ROA:-28.02%
PB:4.70
PE(LYR):-13.84

Loading ...

Xenon Pharmaceuticals announces $500M common shares offering

TIPRANKS
·
Mar 10

Xenon Pharmaceuticals Inc - Commences $500 Mln Underwritten Public Offering

THOMSON REUTERS
·
Mar 10

Press Release: Xenon Pharmaceuticals Announces Proposed Public Offering

Dow Jones
·
Mar 10

Top Midday Gainers

MT Newswires Live
·
Mar 10

A Look At Xenon Pharmaceuticals (XENE) Valuation After Recent Share Price Drift Without Clear Catalyst

Simply Wall St.
·
Mar 10

Raymond James says rival readout gives Biohaven’s Opakalim room to differentiate

TIPRANKS
·
Mar 10

Xenon Pharmaceuticals Is Maintained at Outperform by Baird

Dow Jones
·
Mar 10

Xenon Pharmaceuticals: Blockbuster Potential for Azetukalner After Outperforming Phase 3 Epilepsy Data Drives Target Hike to $80

TIPRANKS
·
Mar 10

Xenon Pharmaceuticals: Azetuklaner’s Strong Phase III Data and Blockbuster Potential Underscore Undervalued Buy Opportunity

TIPRANKS
·
Mar 10

Xenon Pharmaceuticals price target raised to $97 from $63 at Baird

TIPRANKS
·
Mar 10

What's Going On With Biohaven Stock On Monday?

Benzinga_recent_news
·
Mar 09

BUZZ-U.S. STOCKS ON THE MOVE-Biotechs, Agilent, Dow

Reuters
·
Mar 09

Xenon Pharmaceuticals Up Over 45%, on Track for Record High Close -- Data Talk

Dow Jones
·
Mar 09

Xenon Pharmaceuticals rises 41.8%

TIPRANKS
·
Mar 09

Xenon Pharmaceuticals Soars Over 42% at Opening on Positive Phase 3 Epilepsy Drug Results

Stock News
·
Mar 09

BUZZ-U.S. STOCKS ON THE MOVE-Hims & Hers, Live Nation, NovaBridge

Reuters
·
Mar 09

Xenon Pharmaceuticals Exec Says All Four Labeled Doses -10, 15, 20 and 25 Mg - Will Have Flat Pricing, Allowing Physicians to Start and Escalate Doses - Conf Call

THOMSON REUTERS
·
Mar 09

Xenon Pharmaceuticals Exec Says Azetukalner’s Data and Novel Mechanism “Demands” Optimized Pricing, Adding a Prior Therapy Was “Underpriced” - Conf Call

THOMSON REUTERS
·
Mar 09

Xenon Pharmaceuticals Exec Says Co Expects to Be “Extremely Well Positioned” for Launch of Azetukalner - Conf Call

THOMSON REUTERS
·
Mar 09

Xenon Pharmaceuticals Shares Jump 16.5% Premarket After Co's Epilepsy Drug Meets Main Goal in Late-Stage Trial

THOMSON REUTERS
·
Mar 09